Rue de la Rôtisserie 8
Combioxin SA is a clinical-stage company that develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.
Founders: Frédéric Lajaunias and Samareh Lajaunias Azeredo da Silveira
CMO: Antonio Perez
Please click here for clinical trial information..